In almost any organ, tumors can develop and the cancerous cells often spread within the body through the blood or the lymphatic system to form metastases.
Among the most common cancers are: prostate cancer, breast cancer, lung cancer, colon cancer and skin cancer (melanoma).
Tumor associated antigens are expressed by tumor cells and can be recognized by the host's immune system either by immune cells or by antibodies. Although tumor antigens are larger proteins, the detected T-cell epitopes are short peptides. In contrast, antibody epitopes can be linear, represented by relatively short peptide stretches, or they depend on a certain protein conformation that requires longer peptide sequences for proper interaction.
|Immune System Effector||Peptide Length||Peptide Presentation||Peptide Tool|
|CD8+ cytotoxic T cells||8–10 Amino Acids||Presented by MHC class I molecules||Specific Peptide Pools and Libraries|
|CD4+ T cells||12–18 Amino Acids||Presented MHC class II molecules||Specific Peptide Pools and Libraries|
|Antibodies||Small linear peptides or conformational peptide epitopes||MHC independent presentation||Peptide Microarrays or Peptide ELISAs|
JPT’s Clinical Peptides product lines GxP and ISO Plus are produced in production environments that are regulated by an enhanced ISO 9001:2015 quality management system for the stringent product requirements of immunotherapy as well as vaccine and drug development. Depending on the specifics of the immunotherapy concept to be applied, the resulting products have been shown to be applicable in clinical applications.
Cellular Immune Response Profiling
JPT offers tailor-made peptide libraries and peptide pools for cancer research. We provide knowledgeable support to design the appropriate peptide length, purities, pooling strategies and delivery formats for increased shelf life. In addition, we offer GxP Peptides & Pools for immunotherapy and specific clinical applications at attractive pricing.
- Immune monitoring
- Epitope discovery
PepMixes™ for Tumor Associated Antigens (TAA)
Ready-made peptide pools made from overlapping peptide scans through common TAAs such as Erb/Her2, Mage, NY-ESO-1, PSA, Survivin and many more.
PepMixes™ for Tumor Viruses
Ready-made peptide pools made from overlapping peptide scans through antigens of known cancer viruses e.g. EBV and HPV.
Tailored PepMix™ Peptide Pools
Peptide Pools tailored for your specific needs!
> PepMix™ Peptide Pools Product Page
- Vaccine development
- High-throughput T-cell epitope discovery
- Monitoring of cellular immune response
- Clinical trials
Humoral Immune Response Profiling
JPT is the technology leader for peptide microarrays. We offer a range of pre-made catalog peptide microarrays (RepliTope™) for multiple TAAs and production of customized peptide microarrays (PepStar™). In addition, we provide a modular assay and analysis service using high content peptide microarrays, multiwell microarrays and peptide ELISA.
Please visit our service website: Three-Step Seromarker Discovery Service
- Immune monitoring of humoral response
- Profiling of cancer specific samples or antibodies
- Detection of epitopes and epitope spreading
- Vaccine target identification
Catalog RepliTope™ Peptide Microarray for TAAs
JPT’s cancer microarrays display overlapping peptide scans through relevant tumor associated antigens such as Erb/Her2, Mage, NY-ESO-1, PSA, Survivin and many more. We also offer our assay and analysis service using your samples with our peptide microarrays.
Catalog RepliTope™ Peptide Microarray for Tumor Viruses
JPT’s ready-made peptide microarrays display overlapping peptide scans through antigens of known cancer viruses such as EBV and HPV.
> RepliTope™ Peptide Microarrays Product Page
Tailored PepStar™ Peptide Microarrays
You define content and layout, we provide economic and fast production in our regulated clean-room environment. We also offer our assay and analysis service using your samples with your tailored peptide microarray.
In addition to high-content peptide microarrays, JPT offers the development of peptide based enzyme-linked immunosorbent assays (ELISA). This common analytical and highly sensitive immunological assay is well established for proteins but requires detailed experimental know-how for peptides. Peptide ELISA is offered as stand alone service for mapping of epitopes and definition of protein interaction sites or as validation assay to confirm results obtained with JPT’s peptide microarrays.
Cancer & Epigenetics
Histones are part of nucleosomes that build up the chromatin in eukaryotic cells. Histone proteins undergo a variety of post-translational modifications (PTMs e.g. methylation, acetylation, phosphorylation, citrullination). Combinations of these modifications regulate histone interaction with the DNA and other proteins, thus affecting diverse biological processes such as gene regulation, DNA repair, mitosis and meiosis. Abnormal histone modification patterns have been associated with a large number of human malignancies.
Histone Code Peptide Microarray
The Histone Code Peptide Microarray contains more than 3800 histone peptides with and without PTMs. All potential combinations of post-translational modifications are represented. JPT’s comprehensive Histone Code Microarray enables mapping of protein-histone interactions with unprecedented resolution.
Histone Code Peptides
Several hundred histone peptides with and without PTMs are available as purified, high quality, biotinylated or non-biotinylated peptides. Among other applications they can be used for fast and efficient confirmation of microarray results. All peptides are purified and qualified by HPLC-MS and arrive as freeze-dried aliquots.
> Histone Code Product Page
Histone Code Peptide ELISA
The Histone Code Peptide ELISA is designed for rapid screening of PTM-specific antibodies or histone modifying enzymes. The Histone Code Peptide ELISA displays 94 20-meric peptides from human histones H2A, H2B, H3 and H4 for sites reported in the literature featuring different post-translational modifications (PTMs) such as phosphorylation, methylation, acetylation.
Acetylation of lysine residues in proteins and peptides is a posttranslational modification (PTM) that plays a major role in regulating transcription and other metabolic processes. We created two high-density peptide microarrays, each displaying 5599 peptides derived from reported human non-histone acetylation targets.
Identification of biomarkers and profiling of protein expression signatures can be used to develop and improve anti-cancer therapies, diagnostics and to enhance our understanding of carcinogenesis and signaling pathways.
JPT produced sets of proteotypic peptides for the detection and relative quantification of the most relevant tumor associated antigens (TAA) and human cytokines using SRM/MRM assays.
The ready-to-use proteotypic peptide sets and pools are available in two specifications, containing either light or heavy isotope labeled peptides (C-terminal Arg U-13C6; U-15N4 or Lys U-13C6; U-15N2) and is delivered in three 96 well plates.
> Proteotypic Peptide Sets & Pools Product Page
SpikeTides™ are tailored proteotypic peptides, delivered individually or pooled. The proteotypic peptides are synthesized with heavy isotope labeled or light arginine or lysine. For absolute quantification JPT developed a proprietary JPT-tag. The tagged proteotypic peptides enable a cost efficient and more reliable absolute quantification of peptide standards for proteome wide profiling using SRM/MRM proteomic assays.
> SpikeTides™ Proteotypic Peptides Product Page
"An HER2 DNA Vaccine with Evolution-Selected Amino Acid Substitutions Reveals a Fundamental Principle for Cancer Vaccine Formulation in HER2 Transgenic Mice"
Jones et al, Cancer Immunology, Immunotherapy (2019)
"Natural T Cell Autoreactivity to Melanoma Antigens: Clonally Expanded Melanoma-Antigen Specific CD8 + Memory T Cells Can be Detected in Healthy Humans"
Anna Przybyla et al, Cancer Immunology, Immunotherapy (2019)
"Proteome-Wide Onco-Proteogenomic Somatic Variant Identification in ER-Positive Breast Cancer"
Dimitrakopoulos et al, Clinical Biochemistry (2019)
"Vaccine-Induced Memory CD8+ T Cells Provide Clinical Benefit in HER2 Expressing Breast Cancer: a Mouse to Human Translational Study"
Crosby et al, Clinical Cancer Research (2019)
"Rapalog Combined with CCR4 Antagonist Improves Anticancer Vaccines Efficacy"
Beziaud et al, International Journal of Cancer (2018)
"CD11c+ MHCIIlo GM-CSF-Bone Marrow-Derived Dendritic Cells act as Antigen Donor Cells and as Antigen Presenting Cells in Neoepitope-Elicited Tumor Immunity Against a Mouse Fibrosarcoma"
Ebrahimi-Nik et al, Cancer Immunol Immunotherapy (2018)
"Tel-eVax: a Genetic Vaccine Targeting Telomerase for Treatment of Canine Lymphoma"
Impellizeri et al, Journal of Translational Medicine (2018)
"An MRM-Based Cytokeratin Marker Assay as a Tool for Cancer Studies: Application to Lung-Cancer Pleural Effusions"
Perzanowsk et al., Proteomics Clin Appl. (2018) - PMID: 29352525
"Our work focuses on TGF-beta in physiology and cancer as well as the differentiation and expansion of human T cells in vitro for adoptive immunotherapy. For our early phase clinical trials we are in need of T cell EBV specific stimulants having an exceptional quality. JPT's customized PepMix™ Peptide Pools not only proved to deliver excellent performance in our in vitro culture systems but accompanying QC/QA documentation was essential to prepare our application to our regulatory agency."
Dr. Jean-Sébastien Delisle, Université de Montréal, Centre de recherche de l'Hôpital Maisonneuve-Rosemont, Canada
"We utilize customized 15-mer PepMix™ peptide pools encoding for weak tumor associated antigens for immunomonitoring of cancer patients treated with recombinant therapeutic vaccines. Our experience with JPT has been outstanding in regard to product quality and communication with scientific and administrative customer service. JPT is the only company we trust to synthesize the 15-mer peptides and corresponding pools for our clinical trial evaluations."
Benedetto Farsaci, National Cancer Institute, NIH, Bethesda, MD, USA
"The main focus of my research group at the Charité in Berlin is the development of novel immunotherapeutic approaches against cancer and infectious diseases. For reliable monitoring of tumor and virus specific T-cell responses we have a permanent need for peptides and peptide pools that are produced in a regulated environment for application in a clinical environment. JPT has been a long term and dedicated partner in this regard which continuously works on improving it's peptide based services."
Prof. Dr. Carmen Scheibenbogen, Charité Berlin, Germany
The Challenge of Antigen Sequence Diversity: Solutions with ULTRA‐Peptide Libraries
Reimer, Application Note (2015)
Development of a Multiplexed Targeted SRM Assay for NCI’s Top Tumor Associated Antigens
Soderblum et al., Application Note (2015)
Rapid Mimotope Optimization for Pharmacokinetic Analysis of the Novel Therapeutic Antibody IMAB362
Danesshdar et al., Application Note (2014)
A Modular Approach for Epitope Discovery and High-Resolution Profiling of Humoral Immune Responses
Pawlowski et al., Application Note (2013)
Use of High-Density Histone Peptide Arrays for Parsing the Specificity of a Histone-Modifying Enzyme Complex
Wilczek et al., Application Note (2013)
More application notes
Check our list of products,
click and go.
Immune Checkpoint Inhibitors
We launch new PepMixes™ and RepliTopes™ representing immune checkpoint inhibitors hPD-1, PD-L1, PD-L2 and CTLA4!
Performance Control of T-cell Assays
Check the innovative, easy method to produce cellular reference samples for antigen-specific T-cell assays (TERS).
Profile Circulating Antibodies Against 1882 Cancer Peptides with our new RepliTope™ Antigen Collection TAA displaying TAS such as Erb/Her2, Mage, NY-ESO-1, PSA and Survivin.
- Check our new brochure for neo-epitope qualification, cellular and humoral immune monitoring, cellular therapy and more.
Analyze 21 Samples on a Single Microarray with our new RepliTope™ Multiwell Microarrays available for Tumor Antigens and Infections